iBio to Present at the 14th Annual Rodman & Renshaw Conference
NEWARK, Del., Sept. 6, 2012 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) today announced that its President, Robert Erwin , will present a corporate overview at the Rodman & Renshaw 14th Annual Global Investment Conference. Mr. Erwin's presentation is scheduled for Tuesday, September 11, 2012 at 3:40 pm eastern time in the Waldorf Astoria Hotel in New York, NY.
About iBio, Inc.
iBio develops and offers product applications of its iBioLaunch™ and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. Advantages over other systems include: success with proteins difficult or impossible to produce with other methods; broadly applicable to biologics, including monoclonal antibodies, other therapeutic proteins and vaccines; enables rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more. Additional benefits include a practically unlimited surge capacity for remedial action against bioterrorism and pandemic disease; product entry that is unconstrained by traditional process patents, and significantly lower capital and operating costs for comparable production. The iBioModulator platform is complementary to the iBioLaunch platform and enables significantly improved vaccine products with higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at: www.ibioinc.com.
Statements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.
SOURCE iBio, Inc.
More by this Source
iBio Technology Produces Vaccine Candidate for Recently Emerged H7N9 Influenza
May 22, 2013, 07:30 ET
iBio, Inc. closes $4.2 million public offering and terminates At-the-market offering
Apr 29, 2013, 08:46 ET
iBio, Inc. Prices $4.2 Million Public Offering
Apr 23, 2013, 08:45 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.